Table 3.

HBV Markers Among Subjects With HBV Reactivation^a

Markers	CUI-030 (Female, Aged 31) Week						CUI-052 (Male, Aged 41) Week						CUI-143 (Female, Aged 51) Week
	0	4	12	24	36	48	0	4	12	24	36	48	0	4	12	24	36	48
HBsAg	-			-	-	+	-				-		-		-	-	+
Anti-HBs	+++			++	+++		-						+++		+++		++
Anti-HBc	+					++	+			+			+
Anti-HBeb	-			+	-		-						-			-	-
HBV DNA	-		+	++		++	-			+	++		-	-	-	-	-
AST U/L	18	24	12	15	15	14	35	35	26	24	46	30	67	62	92	40	55	26
ALT U/L	22	16	17	11	12	13	25	25	25	28	49	30	61	78	102	38	65	26
HIV-1 RNAc	UD		UD	UD	UD	UD	UD		UD	UD	UD	3715	UD		UD	UD	UD
CD4 countd	317			360		409	734			660			604			657		600
NRTIs	TDF 3TC	None	None	None	None	None	TDF 3TC	None	None	None	None	None	TDF 3TC	None	None	None	None	None

Abbreviations: ALT, alanine transaminases; anti-HBc, total hepatitis B core antibody; anti-HBe, hepatitis B e antibody; anti-HBs, hepatitis B surface antibody; AST, aspartate transaminase; 3TC, lamivudine; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NRTIs, nucleos(t)ide reverse transcriptase inhibitors; TDF, tenofovir disoproxil fumarate; UD, undetectable (<60 copies/mL).

^aAfter study entry, study visits were planned at weeks 4, 12, 24, 36, and 48. Given the retrospective nature of the analysis, stored samples for HBV testing were not available from all study visits; missing time points are blank.

^bWeak anti-HBe reactivity was transiently detected at week 24 and was confirmed by repeat testing of the same sample.

^cPlasma HIV-1 RNA load in copies/mL.

^dCD4 count in cells/mm³.